Head and Neck Oncology

HN: 02 Comparison of outcomes with hypofractionated palliative radiotherapy “christie regimen” versus standard palliative radiation in head and neck squamous cell carcinoma A. Anand Praveen Kumar, N. V. Kalaiyarasi, R. Giridharan Aim: To compare the efficacy and toxicity profile of patients with squamous cell carcinoma of the head and neck (HNSCC) treated with Hypofractionated palliative radiotherapy ‘Christie Regimen’ versus Standard Palliative radiation. {Table 1} HN: 03 Metronomic chemotherapy in recurrent and metastatic head and neck carcinoma Vipul Bansal, Anil Kumar Dhull, Vivek Kaushal, Rajeev Atri Background: Squamous cell head and neck cancer patients with recurrent or metastatic disease require palliative chemotherapy and because of toxic side effects and poor results of conventional chemotherapy, most of the patients are good candidates of oral metronomic chemotherapy. Materials and Methods: In a single arm, prospective observational study, palliative metronomic chemotherapy with oral methotrexate 15 mg/m2/week and oral celecoxib 200 mg twice daily were given to LAHNC patients with recurrent or metastatic disease, having adequate organ function, till the progression of the disease or till intolerable side effects. Target missing and over doses to OARs were reported in the hybrid plans. [...]it can be concluded that Re-CT should be done after noting the remarkable volume changes in the H&N cases.